Pharmacokinetic Principles for Clinical Dosing Decisions

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Pharmacokinetic parameters (bioavailability, Vd, clearance, half-life) are fundamental to predicting drug concentration-time profiles and guiding clinical dosing decisions across veterinary species. Bioavailability dictates dose adjustments when switching routes (e.g., oral vs. IV ketamine), while Vd informs loading dose calculations and interpretation of plasma concentrations, particularly in obese or neonatal patients where body composition alters drug distribution.
• Clearance is the primary determinant of maintenance dosing, directly influencing the required dose rate to achieve steady-state concentrations. Impaired clearance, as seen with hypothermia or organ dysfunction, necessitates dose reduction or interval extension, with the choice dictated by the drug's pharmacodynamic properties (concentration-dependent vs. time-dependent efficacy).
• Antimicrobial efficacy is linked to specific pharmacokinetic/pharmacodynamic (PK/PD) indices, such as AUC/MIC or T > MIC, guiding whether to maximize peak concentrations (e.g., aminoglycosides) or ensure prolonged exposure above the minimum inhibitory concentration (e.g., beta-lactams). This principle is crucial for optimizing bacterial kill and minimizing resistance development, requiring selection of appropriate dosing intervals and doses based on pathogen susceptibility.
• Patient-specific factors significantly alter drug disposition, necessitating dose adjustments beyond simple mg/kg calculations. Age (neonates with immature organ function, geriatrics with reduced clearance), body composition (obesity affecting Vd for lipophilic drugs), and disease states (hypoalbuminemia altering free drug fraction) all require careful consideration for safe and effective therapy.
• Recognizing common dosing errors, such as extrapolating doses between species without accounting for metabolic differences (e.g., deficient glucuronidation in cats) or confusing loading and maintenance doses, is critical for preventing therapeutic failure or toxicity. Vigilant monitoring of clinical response, surrogate markers (e.g., creatinine for nephrotoxicity), and drug concentrations when available are essential for early detection of dosing-related issues.

Every dose administered to a veterinary patient is a prediction. The clinician predicts that a given amount of drug will produce a target concentration at the site of action, sustain that concentration for an adequate duration, and then decline to allow recovery and elimination. Pharmacokinetics supplies the quantitative framework for those predictions. This article explains how the core parameters, bioavailability, volume of distribution, clearance, and half-life, translate into dose selection and adjustment across species. It is written for the practicing veterinarian who needs to interpret label doses, justify extralabel choices, and anticipate why a standard regimen may fail in an individual patient.

The clinical questions addressed here are practical ones. Why does the same milligram per kilogram dose produce different plasma concentrations in a cat versus a dog? When should a dosing interval be extended instead of the dose reduced? How do disease states, age, body composition, and concurrent therapy alter drug disposition in ways that matter for outcome? The article assumes familiarity with clinical terminology and focuses on decision logic instead of species-specific dosing tables. Where numeric thresholds are cited, the system and publishing body are named so the reader can verify current values.

At a Glance

The Dose-Exposure-Response Chain

Pharmacokinetics describes what the body does to a drug, pharmacodynamics describes what the drug does to the body. The two are inseparable in clinical dosing. A dose produces a concentration-time profile, and that profile interacts with a target site to produce an effect. The same dose can produce different profiles in different animals, and the same profile can produce different effects against different pathogens or in different tissues.

For antimicrobial drugs, the relationship between exposure and effect has been formalized into predictive indices. Concentration-dependent agents such as aminoglycosides and fluoroquinolones achieve optimal bacterial kill when the ratio of peak concentration or area under the curve to minimum inhibitory concentration is maximized. Time-dependent agents such as beta-lactams require that free drug concentrations exceed the MIC for a substantial fraction of the dosing interval. These classifications, described in the veterinary pharmacology literature on antimicrobial PK/PD relationships, allow the clinician to choose whether to raise the dose or shorten the interval when a standard regimen is inadequate McKellar and colleagues, pharmacokinetic and pharmacodynamic relationships of antimicrobial drugs. The same framework has been validated across animal infection models and human patients, supporting its transfer to clinical veterinary decision-making Ambrose and colleagues, pharmacokinetics and pharmacodynamics of antimicrobial therapy.

Bioavailability and Route Selection

Bioavailability is the fraction of an administered dose that reaches the systemic circulation in unchanged form. Intravenous administration by definition yields a bioavailability of 1.0. Every other route introduces losses from incomplete absorption, first-pass hepatic metabolism, or degradation within the gastrointestinal lumen or gut wall.

The clinical consequences of low bioavailability are substantial. A drug with 20% oral bioavailability requires five times the oral dose to match an intravenous dose, assuming equal clearance and distribution. More importantly, variability in bioavailability translates directly into variability in exposure. A drug that is consistently but incompletely absorbed may be manageable with a fixed oral dose. A drug whose absorption varies with food, gastric pH, or concurrent medications produces unpredictable plasma concentrations and invites therapeutic failure or toxicity.

Ketamine illustrates the route dependence of bioavailability. Extensive first-pass metabolism makes oral bioavailability poor, while nasal administration produces rapid peak concentrations with relatively high bioavailability Peltoniemi and colleagues, ketamine clinical pharmacokinetics and pharmacodynamics. For a drug with a narrow therapeutic index, choosing a route with predictable absorption is as important as choosing the correct dose.

Volume of Distribution and Loading Doses

Volume of distribution is the apparent space into which a drug disperses. It does not correspond to a physiologic compartment. A drug highly bound to plasma proteins or confined to the vascular space has a small Vd, often near plasma volume. A lipophilic drug that partitions extensively into adipose tissue or binds to tissue proteins can have a Vd many times total body water.

The loading dose equation, loading dose equals target concentration multiplied by Vd, follows directly from this definition. When a rapid therapeutic effect is needed, the loading dose bypasses the gradual accumulation that occurs with repeated maintenance dosing. The Vd also determines how interpretable a measured plasma concentration is. A drug with a large Vd has most of its body burden outside the plasma, so a small change in plasma concentration may reflect a large change in total drug mass.

Body composition matters across species. Obese patients have proportionally more adipose tissue, which can increase Vd for lipophilic drugs and prolong elimination as drug redistributes from fat stores. Neonates have higher total body water and lower protein binding, altering both Vd and the free fraction available at receptors. These differences argue for weight-based adjustments that account for body condition instead of simple total body weight.

Clearance and Maintenance Dosing

Clearance is the volume of plasma from which drug is irreversibly removed per unit time. It is the single most important parameter for maintenance dosing because the maintenance dose rate must equal the rate of elimination to sustain a target average concentration. Clearance is the sum of all eliminating organ function, predominantly hepatic metabolism and renal excretion, and it is the parameter most vulnerable to disease.

Hypothermia provides a clear example of clearance impairment. Systematic review of preclinical and clinical studies shows that therapeutic hypothermia reduces drug clearance, leading to drug and metabolite accumulation in plasma for the majority of drugs studied van den Broek and colleagues, effects of hypothermia on pharmacokinetics. The authors conclude that dosages should be decreased considerably to avoid accumulation. The principle extends beyond hypothermia to any condition that reduces organ perfusion, enzyme activity, or excretory function.

When clearance falls, the clinician faces a choice between reducing the dose and extending the interval. The correct choice depends on the drug's pharmacodynamics. For concentration-dependent drugs, reducing the dose while maintaining the interval preserves peak concentrations but may sacrifice efficacy. For time-dependent drugs, extending the interval while maintaining the dose preserves the duration of effective concentrations but may allow trough levels to fall too low. The decision requires knowing which exposure index drives efficacy for the drug in question.

Half-Life, Steady State, and the Dosing Interval

Half-life is a derived parameter that depends on both clearance and volume of distribution. The relationship, t½ equals 0.693 times Vd divided by Cl, explains why a drug can have a long half-life because it is slowly cleared, widely distributed, or both. A drug with a large Vd and normal clearance can have a longer half-life than a drug with small Vd and impaired clearance.

Steady state is reached after approximately four to five half-lives of regular dosing. This principle governs when to measure drug concentrations, when to expect full therapeutic effect, and when to reassess after a dose change. It also explains why loading doses are valuable for drugs with long half-lives. Without a loading dose, a drug with a 24-hour half-life requires nearly five days to reach steady state, an unacceptable delay for many acute conditions.

The dosing interval is chosen to keep concentrations within a therapeutic window. For drugs with wide windows and predictable pharmacokinetics, such as pregabalin with its linear, dose-proportional absorption and consistent half-life, a fixed interval without titration is practical Ben-Menachem, pregabalin pharmacology and clinical relevance. For drugs with narrow windows or high interindividual variability, the interval must be individualized based on measured concentrations or clinical response.

Patient Factors That Change Parameter Interpretation

The parameters introduced in Part 1 are not fixed properties of a drug. They are conditional values that shift with the patient's physiology, the disease process, and the formulation chosen. A dosing decision made from a formulary value assumes a reference patient that rarely exists in the clinic. The practical task is to identify which parameters are most likely to be perturbed in a given patient and to adjust accordingly.

Body Weight and Body Composition

Clearance and volume of distribution scale with body size, but not linearly across species. Allometric scaling, typically using body weight raised to the 0.75 power for clearance, provides a better cross-species estimate than simple mg/kg extrapolation. Within a species, obesity alters distribution more than clearance. Lipophilic drugs accumulate in adipose tissue, increasing volume of distribution and prolongating terminal half-life without changing clearance. A loading dose based on total body weight may be appropriate for lipophilic agents, but maintenance dosing should reference lean body weight to avoid accumulation. For hydrophilic drugs, both loading and maintenance doses should be based on ideal body weight, since distribution is largely confined to extracellular fluid.

Age and Developmental Status

Neonates have reduced hepatic enzyme capacity, immature renal tubular secretion, and a larger extracellular fluid compartment relative to body weight. These three factors act in the same direction: reduced clearance, increased volume of distribution for hydrophilic drugs, and prolonged half-life. The net effect is that a weight-based dose derived from adult data will produce higher and more sustained exposures in a neonate. The magnitude of the difference depends on the drug's elimination pathway and the species' developmental timeline. For example, a drug cleared predominantly by glomerular filtration will show a different maturation profile than one cleared by a specific cytochrome P450 isoform. documents that hypothermia, a common intervention in neonatal critical care, further impairs clearance and causes drug and metabolite accumulation, with the most striking effect being reduced elimination. Dosing in hypothermic patients should be reduced considerably, and the reduction should be maintained until rewarming is complete.

Geriatric patients present the opposite problem. Reduced renal blood flow, decreased glomerular filtration rate, and diminished hepatic mass all lower clearance. Volume of distribution may increase for lipophilic drugs as body fat fraction rises. The clinical consequence is a longer half-life and a longer time to steady state. A maintenance dose that was appropriate for the same patient at middle age will now produce higher steady-state concentrations. Monitoring for concentration-dependent adverse effects and reassessing the dose after any significant weight change is the practical response.

Disease States That Alter Protein Binding

Many veterinary drugs are highly protein bound, and the free fraction is the pharmacologically active species. Hypoalbuminaemia, uremia, and hepatic disease can all reduce protein binding. For a drug that is normally 95% bound, a fall to 90% bound doubles the free fraction. The immediate effect is a transient increase in pharmacological effect and a higher risk of toxicity. The longer-term effect is more complex: increased free fraction makes more drug available for hepatic metabolism and renal excretion, so total drug clearance rises while free drug concentration returns toward baseline. Measuring total drug concentration in this setting is misleading, since total concentration may be low while free concentration is adequate or even high. For drugs with a narrow therapeutic index and high protein binding, such as phenytoin or some nonsteroidal anti-inflammatory drugs, the clinician should anticipate enhanced effect at standard doses and titrate to clinical response instead of to a total concentration target.

Antimicrobial Dosing: Linking Exposure to Bacterial Kill

Antimicrobial therapy is the area where pharmacokinetic principles have been most rigorously applied to dose optimization. The relationship between drug exposure and bacterial killing is described by three pharmacodynamic indices: the ratio of maximum plasma concentration to minimum inhibitory concentration (Cmax/MIC), the ratio of area under the concentration-time curve over 24 hours to MIC (AUC24/MIC), and the percentage of the dosing interval during which plasma concentrations exceed the MIC (%T > MIC). classifies antimicrobials as concentration-dependent, where increasing concentrations improve bacterial kill, or time-dependent, where exceeding the MIC for a prolonged fraction of the dosing interval correlates with efficacy. For time-dependent drugs, increasing the absolute concentration above a threshold does not improve kill further.

The classification determines the dosing strategy. Concentration-dependent agents, such as aminoglycosides and fluoroquinolones, should be given at high doses with extended intervals to maximize Cmax/MIC or AUC24/MIC. Time-dependent agents, such as beta-lactams, should be given at doses that maintain concentrations above the MIC for most of the interval, which may mean more frequent dosing, continuous infusion, or use of a longer-acting formulation. confirms that these relationships, initially derived from animal infection models, have been confirmed in infected patients and now serve as decision support for dose selection and susceptibility breakpoint setting.

The MIC used in these calculations should come from the specific pathogen isolated from the patient, not from a population-level estimate. When culture results are pending, the clinician must choose a target based on the suspected pathogen and local susceptibility patterns. The AVMA antimicrobial stewardship resources emphasize that judicious use requires selecting an agent and dose that achieves the appropriate exposure at the site of infection while minimizing selection pressure for resistance. In food animals, the choice of dose and duration must also account for withdrawal periods, which are established from pharmacokinetic data in the target species and are legally enforceable in most jurisdictions. The FDA Center for Veterinary Medicine provides approved label information and extralabel use guidance, and the WOAH terrestrial animal health standards address international trade implications of antimicrobial residues.

A Decision Framework for Dose Adjustment

The following framework applies when a patient does not match the reference population for a drug's label dose. The sequence is: identify the parameter most likely to be altered, estimate the direction and magnitude of the change, adjust the relevant dose component, and define a monitoring plan.

Worked Example: Renal Impairment and a Renally Cleared Drug

A dog with chronic kidney disease requires an antimicrobial that is eliminated primarily by renal excretion. The measured creatinine clearance is approximately 50% of the age-matched reference value. Since clearance is directly proportional to maintenance dose rate, the maintenance dose should be reduced by approximately half. The loading dose, which depends on volume of distribution instead of clearance, remains unchanged. The dosing interval can be extended instead of reducing the dose, which preserves peak concentrations while lowering the average steady-state concentration. The choice between these two strategies depends on whether the drug's efficacy is concentration-dependent or time-dependent. For a concentration-dependent drug, extending the interval is preferable. For a time-dependent drug, reducing the dose while maintaining the interval preserves the percentage of time above the MIC.

Worked Example: Hepatic Disease and High First-Pass Metabolism

A cat with portosystemic shunting requires an analgesic that undergoes extensive first-pass hepatic metabolism. notes that ketamine, because of extensive first-pass metabolism, has poor oral bioavailability and is vulnerable to pharmacokinetic drug interactions. The same principle applies to other high-extraction drugs. In a patient with portosystemic shunting, oral bioavailability increases because a larger fraction of the absorbed dose bypasses hepatic extraction. The maintenance dose should be reduced, and the route may need to change to parenteral administration to achieve predictable exposure. The MSD Veterinary Manual provides species-specific guidance on drug selection and dose adjustment in hepatic disease.

Monitoring and Documentation

Therapeutic drug monitoring is available for a limited number of veterinary drugs, including some anticonvulsants and aminoglycosides. When available, it provides the most direct assessment of whether the dose achieves the target exposure. When not available, the clinician must rely on clinical response, adverse effect monitoring, and periodic reassessment of the underlying disease. Documentation should record the dose, the rationale for any deviation from the label dose, the patient factors that prompted the adjustment, and the monitoring parameters and their results. This record supports both continuity of care and defensible prescribing decisions.

Recognized Failure Modes and Early Detection

The most consequential dosing failures are not arithmetic errors but failures of assumption. A dose calculated from a published parameter set assumes the patient resembles the population that generated those parameters. When that assumption fails, the result is either subtherapeutic exposure or toxicity, and both can be silent until organ injury or treatment failure is advanced.

Therapeutic drug monitoring is the most direct detection tool, but it is unavailable for most veterinary drugs. In its absence, early detection depends on scheduled reassessment of clinical effect, measurement of surrogate markers, and vigilance for predictable toxicity. For antimicrobials, failure appears as persistent fever, worsening leukogram, or positive culture at the end of therapy. For drugs with narrow therapeutic indices, such as aminoglycosides, serial creatinine measurement and urinalysis for casts detect nephrotoxicity before azotemia becomes marked. For drugs cleared by the liver, rising bilirubin or prolonged recovery from sedation may signal accumulation before overt hepatotoxicity.

Hypothermia illustrates a failure mode that is easy to miss. Systematic review of preclinical and clinical studies shows that hypothermia impairs clearance for most drugs, producing drug and metabolite accumulation in plasma, and the authors recommend substantial dose reduction during therapeutic hypothermia effects of hypothermia on pharmacokinetics and pharmacodynamics. A patient that is cooled after cardiac arrest, or a small animal recovering from anesthesia with active warming withheld, may therefore require a lower maintenance dose than the same patient at normothermia. The discriminating check is body temperature itself, which is too often treated as a monitoring parameter instead of a dosing parameter.

Common Errors and Corrective Actions

Less experienced clinicians most often err in three directions. First, they extrapolate a dose from a familiar species to an unfamiliar one without checking whether the parameter that drives the dose, usually clearance, differs. A dose that is safe in dogs may be toxic in cats because of deficient glucuronidation, or ineffective in horses because of rapid renal clearance. The corrective action is to consult a species-specific formulary or the MSD Veterinary Manual before prescribing, and to verify that the cited parameter set matches the target species.

Second, they confuse loading dose with maintenance dose. A loading dose is governed by volume of distribution, a maintenance dose by clearance. When a patient needs rapid effect, omitting the loading dose delays steady state by roughly four to five half-lives. When a clinician administers a maintenance dose as a loading dose, the result is transient supratherapeutic exposure. The corrective action is to separate the two calculations explicitly on the treatment sheet.

Third, they ignore the difference between concentration-dependent and time-dependent antimicrobial killing when choosing an interval. For concentration-dependent drugs, the ratio of peak concentration to minimum inhibitory concentration predicts efficacy. For time-dependent drugs, the duration that plasma concentration exceeds the MIC is the governing index pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. Prescribing a time-dependent drug once daily when its half-life is short produces a prolonged sub-MIC interval and selects for resistance. The corrective action is to classify the drug before choosing the interval.

Limitations of the Evidence

The evidence base for veterinary pharmacokinetics is uneven. For some drugs and species, parameter estimates come from small numbers of healthy young adults, and extrapolation to diseased, aged, or very young patients is speculative. The antimicrobial PK/PD literature is comparatively mature, with animal infection models informing dose selection and susceptibility breakpoints pharmacokinetics-pharmacodynamics of antimicrobial therapy, but those models rarely reproduce the full complexity of spontaneous disease, concurrent illness, or polymicrobial infection.

Expert opinion still differs on several points. Whether to dose by body weight or by body surface area for drugs with narrow therapeutic indices remains contested. The clinical relevance of altered protein binding in hypoalbuminaemic patients is debated, because the free drug concentration may remain stable despite a low total concentration. And the application of human-derived therapeutic ranges to veterinary species is accepted for some drugs and rejected for others, with little consensus on where the line should fall.

Referral, Consultation, and Reporting

Referral is warranted when the clinical problem exceeds the available monitoring capacity. A patient that requires therapeutic drug monitoring, intensive pharmacokinetic assessment, or management of a drug interaction that cannot be safely handled in the primary practice should be referred to a specialist or a teaching hospital. Laboratory consultation is appropriate when an unexpected concentration result conflicts with the clinical picture, because assay error, sample timing, or a metabolite cross-reacting with the assay may explain the discrepancy.

Regulatory reporting obligations vary by jurisdiction and by drug. Adverse drug events, particularly those involving approved animal drugs, should be reported through the relevant national pharmacovigilance system. In the United States, the FDA Center for Veterinary Medicine administers adverse event reporting for animal drugs. Antimicrobial use in food animals carries additional stewardship expectations, and professional guidance from the AVMA on antimicrobial use and stewardship should inform prescribing decisions. Extralabel drug use must comply with the applicable regulatory framework, and practitioners should confirm current requirements before prescribing outside the label.

Frequently Asked Questions

How Do I Adjust a Dosing Interval When Therapeutic Drug Monitoring Is Unavailable?

When assay access is limited, use published population pharmacokinetic parameters for the species and drug, then titrate against clinical response and toxicity. For antimicrobials, link observed response to the predicted exposure index, such as the time above MIC for beta-lactams or the AUC to MIC ratio for fluoroquinolones, as described in reviews of antimicrobial PK/PD relationships. Monitor organ function, especially renal clearance, as a surrogate for drug elimination. Document the predicted exposure, the clinical endpoint used, and the date of reassessment. If response is inadequate, verify compliance, reassess the diagnosis, and only then adjust dose or interval. Avoid repeated empirical escalation without a defined endpoint.

What Should I Do When Cost Limits the Choice of Drug or Monitoring Plan?

Select the drug with the most forgiving pharmacokinetic profile within the budget. A drug with a wide therapeutic index and linear kinetics, such as pregabalin with its predictable dose-proportional exposure, may permit less frequent monitoring than a narrow-index alternative pregabalin pharmacology and clinical relevance. Extend the dosing interval instead of reduce the individual dose for time-dependent antimicrobials, since sub-MIC troughs select for resistance. For concentration-dependent drugs, maintain the full dose but lengthen the interval. State the compromise in the medical record, including the predicted exposure shortfall and the monitoring plan. Revisit the choice if the patient fails to respond.

How Does the Dosing Approach Differ Between a Dog and a Horse for the Same Drug?

Body weight scaling is not sufficient across species. Hepatic enzyme expression, renal transport, and gastrointestinal transit differ markedly, so extrapolation from one species to another risks underdosing or toxicity. Consult species-specific formularies and the MSD Veterinary Manual for disposition data in the target species. For food animals, withdrawal intervals must be based on the approved label for that species and route, extralabel use requires a valid veterinary-client-patient relationship and residue avoidance planning under FDA CVM regulatory guidance. When no species-specific data exist, start with the most conservative published estimate and monitor response and adverse effects closely.

What Records Should I Keep When Making an Off-Label Dosing Decision?

Record the clinical indication, the published basis for the dose, the calculated exposure estimate, and the monitoring plan. Note the patient's body weight, organ function status, and concurrent medications. For food animals, document the extralabel drug use justification, the assigned withdrawal interval, and the client's written acknowledgment of that interval, consistent with FDA CVM animal drug information. Include the date of reassessment and the measured or observed outcome. This record supports continuity of care, defends the clinical decision if questioned, and provides the data needed to adjust the next dose. Update the record at every recheck, also at the initial prescription.

How Do I Explain a Pharmacokinetic Dose Adjustment to a Client Without Oversimplifying?

Frame the explanation around the drug's job and the body's handling of it. State that the dose is based on how quickly the patient's body clears the drug, and that disease changes that speed. Use a concrete analogy, such as a sink draining at a different rate, and then state the specific change: the same dose given less often, or a lower dose given at the same interval. Explain what the client should watch for, both therapeutic effect and toxicity. Avoid guarantees. Direct the client to observe and report instead of adjust medication themselves. This preserves the professional decision while giving the owner a clear role in monitoring.

When Should I Refer a Case for Pharmacokinetic Consultation?

Refer when the patient has failed two or more evidence-based dosing adjustments, when organ dysfunction is severe and no published guidance exists for that combination, or when therapeutic drug monitoring is indicated but unavailable locally. Refer also when polypharmacy creates competing clearance pathways and the risk of toxicity is high. A clinical pharmacologist or specialist service can model exposures using population kinetics and recommend a tailored regimen. For regulatory questions involving food animals, consult the WOAH terrestrial animal health standards and national authorities before acting. Referral is not a failure of clinical reasoning, it is a mechanism to reduce uncertainty when the margin for error is small.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy.. 2016.
• Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.. 2004.
• Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences.. 1980.
• Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies.. 2010.
• Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's also for mice anymore.. 2007.
• Pregabalin pharmacology and its relevance to clinical practice.. 2004.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Pharmacokinetics in Veterinary Patients: Clinical Application of Drug Disposition
• Dose Adjustment in Hepatic Disease: Pharmacokinetic Principles for Veterinary Patients
• Pharmacokinetic Considerations for Drug Dosing in Neonatal and Pediatric Veterinary Patients
• Pharmacokinetic Drug Interactions in Veterinary Patients: Mechanisms and Clinical Relevance
• Antimicrobial Stewardship in Food Animals: Principles and Practical Application

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.